GlaxoSmithKline is having trouble recruiting patients for a large clinical trial of its controversial diabetes drug Avandia, the Wall Street Journal reports this morning.
The drug has been linked to an increased risk of heart attack, but GSK officials have said it's a safe and effective product. Federal regulators are considering whether to halt the so-called TIDE clinical trial early because of Avandia's health risks.
Two sites, including Wake Forest University Baptist Medical Center in Winston-Salem, have pulled out of the safety study, GSK reports. The British company, which has its North American headquarters in Research Triangle Park, didn't name the second site.